Moderna, Inc.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
325 BINNEY STREET, CAMBRIDGE, MA, 02142
Mailing Address
325 BINNEY STREET, CAMBRIDGE, MA, 02142
Phone
6177146500
Fiscal Year End
1231
EIN
813467528
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 16, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 25, 2026 | View on SEC |
Annual Reports
10-K
February 20, 2026
- Successful launch of RSV vaccine in 2025, diversifying revenue beyond Spikevax.
- Aggressive investment in a broad pipeline with over 40 programs, 25 in clinical development, including late-stage influenza and oncology.
Material Events
8-K
Legal Issue
March 5, 2026
High Impact
- Moderna secures a permanent, royalty-free license to crucial LNP technology for its entire infectious disease vaccine pipeline.
- The settlement removes a significant legal overhang, allowing Moderna to focus on R&D, manufacturing, and commercialization without distraction.
8-K
Other
February 11, 2026
High Impact
- Moderna's strategic goal to diversify its product portfolio beyond the COVID-19 vaccine.
- Targeting the multi-billion dollar seasonal flu vaccine market with mRNA-1010.
Insider Trading
STRONG SELL
4 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2836)
Adaptive Biotechnologies Corp
ADPT
Biological Products, (No Diagnostic Substances)
Voyager Therapeutics, Inc.
VYGR
Biological Products, (No Diagnostic Substances)
Immunovant, Inc.
IMVT
Biological Products, (No Diagnostic Substances)
Cardiff Oncology, Inc.
CRDF
Biological Products, (No Diagnostic Substances)
Kodiak Sciences Inc.
KOD
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.